FGF21 and metabolic dysfunction-associated steatotic liver disease: Lower M30 level [0.675 (95%CI 0.563–0.788; P = 0.006)] was an independent predictor of NAFLD remission during follow-up while FGF21 [0.574 (95%CI 0.455–0.693; P = 0.243)] and M65ED [0.469 (95%CI 0.348–0.589; P = 0.614)] were not predictive of NAFLD remission (Fig. 2b).